AI-based lung function tester developer TR announced that it has secured a total of USD 1.92 million (KRW 2.5 billion) in investment in its Series A funding round.

This investment round saw participation from Capstone Partners, Hallym University Technology Holdings, Infobank, Korea Credit Guarantee Fund, Digital Healthcare Partners (DHP), and Seoul Business Agency (SBA).

TR has solidified its position as a specialized medical device company for respiratory care, with its flagship product ‘The Spirokit,’ as well as ‘The Neb,’ a nebulizer integrated with IoT, and ‘The Aerokit,’ a spacer for inhaler assistance.

‘The Spirokit,’ the representative product, is an AI-based lung function tester developed to aid in the early diagnosis of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It has received high evaluations for its ability to perform highly accurate lung function and disease tests even by non-respiratory specialists.

Byung-soo Kim, CEO of TR, expressed his pleasure, stating, “We are delighted to have the company’s value recognized through successful investment attraction. This investment will enable us to further strengthen the productivity and distribution network of our launched products, upgrade the performance of the existing The Spirokit, and stably proceed with the launch of products currently under development, such as the exhaled nitric oxide (FeNO) tester and pulmonary diffusion capacity (DLCO) tester.”

TR is currently accelerating its expansion into overseas markets for The Spirokit, including Vietnam, Indonesia, and the United States, aiming for USD 3.85 million (KRW 5 billion) in sales by 2026. Furthermore, the company aims to solidify its product pipeline to become the leading respiratory medical device company in Korea and a globally recognized representative company in respiratory-related medical devices.